We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Diatron MI Plc

Develops, manufactures and markets hematology analyzers, clinical chemistry analyzers, and associated reagents for hu... read more Featured Products: More products

Download Mobile App





Diatron Presents High-Quality Hematology and Clinical Chemistry Products

By LabMedica International staff writers
Posted on 29 Jul 2025

Diatron (Budapest, Hungary) is exhibiting at ADLM 2025, where the company is presenting its newly launched clinical chemistry analyzer alongside other high-quality hematology products. More...

Diatron’s new clinical chemistry analyzer, the P780, which is being introduced at the show, is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories. Ideal for a variety of lab sizes, from medium to large, the P780 is engineered for high reliability, offering an innovative and scalable solution. As Diatron’s flagship clinical chemistry analyzer, the P780 excels in maximum throughput, which is enabled by uninterrupted photometric tests and an independent ISE arm. As a result, the P780 allows continuous operation under demanding workloads, ensuring fast turnaround times without compromising accuracy. The system is equipped with a dual concentric reagent tray with cooled positions for calibrators and controls, plus an optional Auto Filling Draining Module that enables nonstop operation and reduces manual work.

A built-in panel PC with a touchscreen interface helps to minimize the instrument’s footprint and streamline daily use. The system features advanced software, delivering an intuitive, easy-to-use interface and a comprehensive dashboard, with real-time worklist monitoring and flexible workflow management tools to simplify daily lab procedures. Diatron is also showcasing Aquila, its innovative and revolutionary 3-part differential hematology analyzer that can be used in any testing location and application where high-quality CBC results are desired. The company’s latest technology offers the optimal testing solution for both the experienced and inexperienced user, and practices that require a high-quality hematology analyzer.

Diatron is also highlighting its Aquarius 3 hematology analyzer that combines technology and simplicity to give all the required information, reducing the unnecessary steps to a minimum whilst maintaining the balance between cost and benefit for patients and users alike. With a sleek, new modern design, the Aquarius 3 interface offers a positive touch and feeling, with all actions designed to increase efficiency, saving time to perform other important tasks. The new Aquarius 3 software features a high level of patient management and workflow optimization to avoid repetition whilst only having a small reagent consumption.

Related Links:
Diatron


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automated Urinalysis Solution
UN-9000
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.